Gilead Sciences, Inc. (Nasdaq: GILD) today announced new research to be presented at The Liver Meeting® 2024, hosted by the ...

Three years after raising $100 million in series A funds, the Atlas Venture-backed biotech has chosen a lead drug candidate.

Ultra-processed food consumption in obese adolescents is linked to insulin resistance and liver disease, stressing the need ...

Experiment suggests liver could be key to restarting neural activities, a discovery that could pave the way for new cardiac ...

The London-based biotechnology company said the non-dilutive funding will support its ongoing development of its lead gene therapy, GF-1002, for the treatment of metabolic associated steatohepatitis, ...

KOCHI: George (name changed), was 55-years-old when he was diagnosed with fatty liver. Since he was a teetotaller, he did not ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended elafibranor 80mg ...

Professor Ramou Njie made this disclosure recently during her presentation as part of activities marking liver cancer ...

Milk thistle, known for its silymarin content, is celebrated for protecting the liver against damage, reducing inflammation, ...

Diagnosing antibody-mediated rejection in liver transplant recipients is hindered by a lack of biomarkers and co-occurrence ...

A low-dose triple polypill containing telmisartan, amlodipine, and indapamide led to clinically meaningful improvements in ...

BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological ...